Literature DB >> 27712010

Hepatic manifestations of inflammatory bowel diseases.

Sophie Restellini1, Olivier Chazouillères2, Jean-Louis Frossard1.   

Abstract

Inflammatory bowel diseases are associated with various hepatobiliary disorders, reported both in Crohn's disease and ulcerative colitis. They may occur at any moment in the natural course of the disease. The prevalence of liver dysfunction rises from 3% to 50% accordingly to definitions used in different studies. Fatty liver is considered as the most common hepatobiliary complication in inflammatory bowel diseases while primary sclerosing cholangitis is the most specific one. Less frequently, inflammatory bowel diseases-associated hepatobiliary disorders include: autoimmune hepatitis/ primary sclerosing cholangitis overlap syndrome, IgG4-associated cholangiopathy, primary biliary cholangitis, hepatic amyloidosis, granulomatous hepatitis, cholelithiasis, portal vein thrombosis and liver abscess. The spectrum of these manifestations varies according to the type of inflammatory bowel diseases. Treatments of inflammatory bowel diseases may cause liver toxicity, although incidence of serious complications remains low. However, early diagnosis of drug-induced liver injury is of major importance as it affects future clinical management. When facing abnormal liver tests, clinicians should undertake a full diagnostic work-up in order to determine whether the hepatic abnormalities are related to the inflammatory bowel diseases or not. Management of hepatic manifestations in inflammatory bowel diseases usually involves both hepatologists and gastroenterologists because of the complexity of some situations.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  drug-induced liver injury; hepatotoxicity; inflammatory bowel disease; liver disease; primary sclerosing cholangitis

Mesh:

Year:  2016        PMID: 27712010     DOI: 10.1111/liv.13265

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  16 in total

Review 1.  Hepatic Manifestations of Inflammatory Bowel Disease.

Authors:  Parita Patel; Sushila Dalal
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-05-01

Review 2.  Practical clinical approach to the evaluation of hepatobiliary disorders in inflammatory bowel disease.

Authors:  Afif Yaccob; Amir Mari
Journal:  Frontline Gastroenterol       Date:  2018-10-09

3.  Neutralization of IL-15 abrogates experimental immune-mediated cholangitis in diet-induced obese mice.

Authors:  José L Reyes; Danielle T Vannan; Tina Vo; Aliya Gulamhusein; Paul L Beck; Raylene A Reimer; Bertus Eksteen
Journal:  Sci Rep       Date:  2018-02-15       Impact factor: 4.379

Review 4.  Hepatobiliary Manifestations and Complications in Inflammatory Bowel Disease: A Review.

Authors:  Fotios S Fousekis; Vasileios I Theopistos; Konstantinos H Katsanos; Epameinondas V Tsianos; Dimitrios K Christodoulou
Journal:  Gastroenterology Res       Date:  2018-04-07

5.  Ficus pandurata Hance Inhibits Ulcerative Colitis and Colitis-Associated Secondary Liver Damage of Mice by Enhancing Antioxidation Activity.

Authors:  Weibo Dai; Xinyi Zhan; Weijie Peng; Xin Liu; Weiwen Peng; Quanxi Mei; Xianjing Hu
Journal:  Oxid Med Cell Longev       Date:  2021-12-18       Impact factor: 6.543

6.  Arterial Stiffness in Inflammatory Bowel Disease: An Updated Systematic Review and Meta-Analysis.

Authors:  Qiongqiong Lu; Rui Shi; Tangyou Mao; Zhibin Wang; Zhongmei Sun; Xiang Tan; Yi Wang; Junxiang Li
Journal:  Turk J Gastroenterol       Date:  2021-05       Impact factor: 1.555

7.  Frequency of Hepatobiliary Manifestations and Concomitant Liver Disease in Inflammatory Bowel Disease Patients.

Authors:  Juliana Silva; Beatriz S Brito; Isaac Neri de N Silva; Viviane G Nóbrega; Maria Carolina S M da Silva; Hemerson Dyego de N Gomes; Flora Maria Fortes; Andrea M Pimentel; Jaciane Mota; Neogélia Almeida; Valdiana C Surlo; André Lyra; Raquel Rocha; Genoile O Santana
Journal:  Biomed Res Int       Date:  2019-01-31       Impact factor: 3.411

Review 8.  Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders.

Authors:  Stefano Mazza; Sara Soro; Maria Chiara Verga; Biagio Elvo; Francesca Ferretti; Fabrizio Cereatti; Andrea Drago; Roberto Grassia
Journal:  World J Hepatol       Date:  2021-12-27

Review 9.  Liver manifestations and complications in inflammatory bowel disease: A review.

Authors:  Rui Gaspar; Catarina Castelo Branco; Guilherme Macedo
Journal:  World J Hepatol       Date:  2021-12-27

Review 10.  Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management.

Authors:  Gerhard Rogler; Abha Singh; Arthur Kavanaugh; David T Rubin
Journal:  Gastroenterology       Date:  2021-08-03       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.